VIA
MLYS icon

Virtus Investment Advisers’s Mineralys Therapeutics MLYS Stock Holding History

Virtus Investment Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
13,853
+6,464
+87% +$177K 0.09% 318
2026
Q1 		$200K Buy
7,389
+180
+2% +$5.28K 0.06% 353
2025
Q4 		$262K Sell
7,209
-417
-5% -$16.7K 0.07% 308
2025
Q3 		$289K Buy
7,626
+1,324
+21% +$28.6K 0.08% 241
2025
Q2 		$85.3K Sell
6,302
-7,192
-53% -$104K 0.03% 400
2025
Q1 		$214K Buy
+13,494
New +$155K 0.06% 258

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Virtus Investment Advisers's MLYS Position: Q2 2026 in Review

Virtus Investment Advisers increased its Mineralys Therapeutics (MLYS) stake by 87% in Q2 2026, buying an estimated $177K and bringing the position to 13,853 shares worth $374K. The position accounts for 0.09% of the portfolio, ranked #318.

Virtus Investment Advisers first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Virtus Investment Advisers held 13,853 shares of Mineralys Therapeutics worth $374K as of Q2 2026.
  • Virtus Investment Advisers bought 6,464 Mineralys Therapeutics shares in Q2 2026, an estimated $177K.
  • Mineralys Therapeutics made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #318 holding.
  • Virtus Investment Advisers first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.